fda compounding semaglutide warning september 2025 The has received reports of adverse events after patients used compounded versions of semaglutide. Some compounders may also be using unapproved salt forms. Patients should avoid compounded when an FDA-approved August 11, 2025: The FDA

The majority of patients experience significant weight regain if treatment with GLP-1 medications stops, and it is unclear if there will be a sustainable, long-term access to GLP-1 treatment for obesity for Medicare beneficiaries. Nielsen says she anticipates demand for the GLP-1 Bridge program will be high, making it important to see your healthcare provider for an evaluation now

Semaglutide may be an option for adults who struggle with weight loss despite diet and exercise

Ready to Strengthen Nutrition Services in Your Practice

In 2022, the company that owns the patent of Eriomin funded a small trial involving 45 people, concluding that those who took it over a 12-week period had lower blood glucose and higher GLP-1 than those who took a placebo

The clinical evidence base for retatrutide is still maturing

In that blind spot, experts estimate hundreds of thousands of Americans are taking medicine that hasnt been vetted by the FDA for safety and effectiveness the way a typical prescription drug would be